' 
SCIENTIFIC SCORE
Likely Very Effective
Based on 10 Researches
9
USERS' SCORE
Good
Based on 5 Reviews
8.6
Supplement Facts
Serving Size: 1 Vegetable Capsule
Amount Per Serving
%DV
Iron (as iron bisglycinate chelate†)
25 mg
139%
Top Medical Research Studies
9
SPIO improves lymph node detection
Use of superparamagnetic iron oxide for sentinel lymph node detection following neoadjuvant systemic therapy. A systematic review and meta-analysis.
Directly addresses SPIO effectiveness
We explored the effectiveness of superparamagnetic iron oxide (SPIO) in detecting sentinel lymph nodes in breast cancer patients who had undergone neoadjuvant systemic therapy before surgery. This study included a systematic review of multiple databases and focused on comparing SPIO to the standard methods involving radioisotope and blue dye.
Our findings highlight that SPIO successfully identified sentinel lymph nodes in about 98.1% of cases, while the standard method achieved a detection rate of 94.6%. When examining the number of lymph nodes retrieved, SPIO demonstrated superior performance, with an average of 2.26 nodes detected compared to 1.86 with the conventional approach.
The overall quality of the studies reviewed was considered good, indicating that we can reliably say SPIO can be safely and effectively adopted in clinical practice for these patients. This suggests a promising alternative in medical settings, where identifying lymph nodes accurately is crucial for treatment planning.
Our findings highlight that SPIO successfully identified sentinel lymph nodes in about 98.1% of cases, while the standard method achieved a detection rate of 94.6%. When examining the number of lymph nodes retrieved, SPIO demonstrated superior performance, with an average of 2.26 nodes detected compared to 1.86 with the conventional approach.
The overall quality of the studies reviewed was considered good, indicating that we can reliably say SPIO can be safely and effectively adopted in clinical practice for these patients. This suggests a promising alternative in medical settings, where identifying lymph nodes accurately is crucial for treatment planning.
Read More
9
Iron oxide NPs enhance cancer treatment
Universal Chiral Nanopaint for Metal Oxide Biomaterials.
Study highlights nanopaint effects
We delved into how iron oxide nanoparticles (NPs), when enhanced with a special chiral nanopaint, can impact cancer treatment. Our focus was on comparing two forms of these nanoparticles: the d-nanopainted versions and their l-nanopainted counterparts. We discovered that the d-nanopainted iron oxide NPs had over 50% higher cellular uptake by cancer cells. This increase was linked to the way these chiral NPs interacted specifically with receptors on the cell surfaces.
Moreover, in testing on living subjects, the d-nanopainted iron oxide NPs demonstrated a striking four-fold improvement in anticancer efficiency through magnetic hyperthermia. This was attributed to their better ability to adhere to tumor tissues compared to the l-nanopainted version. Thus, we see that the innovative use of chiral nanopaint appears to significantly enhance the effectiveness of iron oxide nanoparticles in cancer treatments, marrying magnetism with chirality for promising biomedical applications.
Moreover, in testing on living subjects, the d-nanopainted iron oxide NPs demonstrated a striking four-fold improvement in anticancer efficiency through magnetic hyperthermia. This was attributed to their better ability to adhere to tumor tissues compared to the l-nanopainted version. Thus, we see that the innovative use of chiral nanopaint appears to significantly enhance the effectiveness of iron oxide nanoparticles in cancer treatments, marrying magnetism with chirality for promising biomedical applications.
Read More
9
Deferasirox induces cancer cell death
Deferasirox Targets TAOK1 to Induce p53-Mediated Apoptosis in Esophageal Squamous Cell Carcinoma.
Significant focus on iron's role
We investigated the effect of Deferasirox, an iron chelator, on esophageal squamous cell carcinoma (ESCC), a particularly aggressive form of cancer with limited treatment options. Our study focused on how this compound interacts with a protein called TAOK1, known for its role in cancer growth.
We observed that Deferasirox significantly slows down the growth and colony formation of ESCC cells in both a dose-dependent and time-dependent manner. The mechanism behind this involves Deferasirox directly binding to TAOK1, which in turn decreases its activity.
Furthermore, we learned that when TAOK1 activity is reduced—whether through Deferasirox treatment or by using a special virus to knock down the gene—it leads to an increase in cell death linked to the tumor suppressor protein p53. This suggests the potential for Deferasirox as a means to induce cancer cell apoptosis, evidenced by increased levels of several pro-apoptotic signals.
In animal studies using human tumor samples, we found that Deferasirox could shrink tumors without causing harm, and further analysis confirmed its effects on TAOK1 and p53 in the tissue. Our findings open the door for using Deferasirox as a new strategy in treating ESCC, although we should note that we could not fully isolate the effect of iron alone from the overall efficacy of DFO in this context.
We observed that Deferasirox significantly slows down the growth and colony formation of ESCC cells in both a dose-dependent and time-dependent manner. The mechanism behind this involves Deferasirox directly binding to TAOK1, which in turn decreases its activity.
Furthermore, we learned that when TAOK1 activity is reduced—whether through Deferasirox treatment or by using a special virus to knock down the gene—it leads to an increase in cell death linked to the tumor suppressor protein p53. This suggests the potential for Deferasirox as a means to induce cancer cell apoptosis, evidenced by increased levels of several pro-apoptotic signals.
In animal studies using human tumor samples, we found that Deferasirox could shrink tumors without causing harm, and further analysis confirmed its effects on TAOK1 and p53 in the tissue. Our findings open the door for using Deferasirox as a new strategy in treating ESCC, although we should note that we could not fully isolate the effect of iron alone from the overall efficacy of DFO in this context.
Read More
Most Useful Reviews
9.5
Iron level recovery
I ordered this for a cancer patient whose iron was depleted due to chemotherapy. We tried other kosher iron supplements without success until we switched to Solgar gentle iron. Her levels began to rise, and she no longer needs transfusions after taking it first thing in the morning with vitamin C.
Read More
9.5
Significant improvement
These pills are excellent. My father is a cancer patient and was incredibly weak with a hemoglobin level of just 50 in August. After two months of taking these pills, his hemoglobin rose to 106. I’m really pleased with the results.
Read More
8.8
Improved blood test
My mother underwent complete esophageal removal due to cancer, which led to severe anaemia. Despite trying various iron supplements and treatments over three years, her condition did not improve. However, after consistently drinking this supplement, her blood test results improved during regular health checks a few months later. I also advised others to consume it after meals to alleviate stomach discomfort, which seems to be effective. I’ve noticed a reduction in dizziness too. However, it’s currently out of stock, and I hope it is restocked soon.
Read More
Medical Researches
SCIENTIFIC SCORE
Likely Very Effective
Based on 10 Researches
9
9.5
Iron nanoparticles enhance cancer therapy
Synergistic effects of paclitaxel and platelet-superparamagnetic iron oxide nanoparticles for targeted chemo-hyperthermia therapy against breast cancer.
Iron's role in targeted treatments
We explored an innovative approach to battling breast cancer by developing a drug delivery system that uses superparamagnetic iron oxide nanoparticles. These nanoparticles are coated with platelet membranes, allowing them to specifically target tumor sites while harnessing the benefits of magnetic hyperthermia and chemotherapy.
In our study, we found that these platelet membrane-coated nanoparticles facilitated the controlled release of the chemotherapy drug Paclitaxel (PTX). Notably, when the pH shifted to acidic conditions, similar to those found in tumor environments, the release of PTX increased significantly. We observed enhanced cellular uptake of these nanoparticles and remarkable cytotoxic effects against cancer cells, particularly when combined with an alternating magnetic field.
Our results indicated that this combination therapy could inhibit tumor growth effectively, with a rate reaching nearly 92.14%. This suggests a promising pathway to minimize the harmful side effects commonly associated with traditional chemotherapy, maximizing the therapeutic impact by using iron-based nanoparticles to enhance treatment outcomes.
In our study, we found that these platelet membrane-coated nanoparticles facilitated the controlled release of the chemotherapy drug Paclitaxel (PTX). Notably, when the pH shifted to acidic conditions, similar to those found in tumor environments, the release of PTX increased significantly. We observed enhanced cellular uptake of these nanoparticles and remarkable cytotoxic effects against cancer cells, particularly when combined with an alternating magnetic field.
Our results indicated that this combination therapy could inhibit tumor growth effectively, with a rate reaching nearly 92.14%. This suggests a promising pathway to minimize the harmful side effects commonly associated with traditional chemotherapy, maximizing the therapeutic impact by using iron-based nanoparticles to enhance treatment outcomes.
Read More
9
Iron oxide NPs enhance cancer treatment
Universal Chiral Nanopaint for Metal Oxide Biomaterials.
Study highlights nanopaint effects
We delved into how iron oxide nanoparticles (NPs), when enhanced with a special chiral nanopaint, can impact cancer treatment. Our focus was on comparing two forms of these nanoparticles: the d-nanopainted versions and their l-nanopainted counterparts. We discovered that the d-nanopainted iron oxide NPs had over 50% higher cellular uptake by cancer cells. This increase was linked to the way these chiral NPs interacted specifically with receptors on the cell surfaces.
Moreover, in testing on living subjects, the d-nanopainted iron oxide NPs demonstrated a striking four-fold improvement in anticancer efficiency through magnetic hyperthermia. This was attributed to their better ability to adhere to tumor tissues compared to the l-nanopainted version. Thus, we see that the innovative use of chiral nanopaint appears to significantly enhance the effectiveness of iron oxide nanoparticles in cancer treatments, marrying magnetism with chirality for promising biomedical applications.
Moreover, in testing on living subjects, the d-nanopainted iron oxide NPs demonstrated a striking four-fold improvement in anticancer efficiency through magnetic hyperthermia. This was attributed to their better ability to adhere to tumor tissues compared to the l-nanopainted version. Thus, we see that the innovative use of chiral nanopaint appears to significantly enhance the effectiveness of iron oxide nanoparticles in cancer treatments, marrying magnetism with chirality for promising biomedical applications.
Read More
9
Iron management enhances cancer immunity
Inhibiting Neutrophil Extracellular Trap Formation through Iron Regulation for Enhanced Cancer Immunotherapy.
Focus on iron's combined effects
We explored how iron metabolism in neutrophils can influence cancer treatment, particularly its role in the formation of neutrophil extracellular traps (NETs). These NETs are problematic because they can suppress immune responses within tumors, creating significant hurdles for cancer therapies.
Our approach involved developing a unique peptide-drug conjugate known as a transformable iron nanochelator (TIN). This innovative tool is designed to manage the iron levels in neutrophils, ultimately aiming to inhibit NET formation. We were excited to see that the TIN utilizes a process where it transforms from nanoparticles into nanofibers. These structural changes facilitate precise regulation of iron, effectively reducing NET formation and enhancing immune responses in our model.
Additionally, we found that combining the TIN with other treatments, like protein arginine deiminase 4 inhibitors and anti-PD-L1 therapy, significantly improved therapeutic outcomes. This joint strategy appears promising, opening the door for a new perspective on immune modulation by focusing specifically on iron metabolism in cancer therapy.
Our approach involved developing a unique peptide-drug conjugate known as a transformable iron nanochelator (TIN). This innovative tool is designed to manage the iron levels in neutrophils, ultimately aiming to inhibit NET formation. We were excited to see that the TIN utilizes a process where it transforms from nanoparticles into nanofibers. These structural changes facilitate precise regulation of iron, effectively reducing NET formation and enhancing immune responses in our model.
Additionally, we found that combining the TIN with other treatments, like protein arginine deiminase 4 inhibitors and anti-PD-L1 therapy, significantly improved therapeutic outcomes. This joint strategy appears promising, opening the door for a new perspective on immune modulation by focusing specifically on iron metabolism in cancer therapy.
Read More
9
Iron treatment enhances tumor immunity
YTHDF1-targeting nanoassembly reverses tumoral immune evasion through epigenetics and cell cycle modulation.
Effectiveness influenced by combined methods
We explored the effects of iron treatment on cancer, specifically looking at how it influences immune responses in tumor cells. Our focus was on YTHDF1, a protein that plays a key role in tumor cell immune evasion by promoting the degradation of MHC-I molecules, which are crucial for immune recognition.
To tackle this issue, we developed a unique nanoassembly that combines Deferasirox (an FDA-approved iron chelator) with YTHDF1 siRNA. This innovative approach interferes with iron metabolism while simultaneously targeting YTHDF1, leading to cell cycle arrest in tumor cells.
The results were encouraging: knocking down YTHDF1 not only increased MHC-I molecule expression by 2.5 times but also enhanced the overall immune response. This means less degradation of important antigens, which strengthens T cell activity against tumors. Following treatment, we observed a significant increase in CD8 T cells in the tumors and effector memory T cells in the spleen, indicating a robust anti-tumor immune effect.
While the combination of iron regulation with epigenetic modulation was potent, it left us pondering the isolated impact of iron alone in this complex interplay. Nonetheless, these findings demonstrate a promising avenue for improving breast cancer treatment and potentially addressing recurrence and metastasis.
To tackle this issue, we developed a unique nanoassembly that combines Deferasirox (an FDA-approved iron chelator) with YTHDF1 siRNA. This innovative approach interferes with iron metabolism while simultaneously targeting YTHDF1, leading to cell cycle arrest in tumor cells.
The results were encouraging: knocking down YTHDF1 not only increased MHC-I molecule expression by 2.5 times but also enhanced the overall immune response. This means less degradation of important antigens, which strengthens T cell activity against tumors. Following treatment, we observed a significant increase in CD8 T cells in the tumors and effector memory T cells in the spleen, indicating a robust anti-tumor immune effect.
While the combination of iron regulation with epigenetic modulation was potent, it left us pondering the isolated impact of iron alone in this complex interplay. Nonetheless, these findings demonstrate a promising avenue for improving breast cancer treatment and potentially addressing recurrence and metastasis.
Read More
9
SPIO improves lymph node detection
Use of superparamagnetic iron oxide for sentinel lymph node detection following neoadjuvant systemic therapy. A systematic review and meta-analysis.
Directly addresses SPIO effectiveness
We explored the effectiveness of superparamagnetic iron oxide (SPIO) in detecting sentinel lymph nodes in breast cancer patients who had undergone neoadjuvant systemic therapy before surgery. This study included a systematic review of multiple databases and focused on comparing SPIO to the standard methods involving radioisotope and blue dye.
Our findings highlight that SPIO successfully identified sentinel lymph nodes in about 98.1% of cases, while the standard method achieved a detection rate of 94.6%. When examining the number of lymph nodes retrieved, SPIO demonstrated superior performance, with an average of 2.26 nodes detected compared to 1.86 with the conventional approach.
The overall quality of the studies reviewed was considered good, indicating that we can reliably say SPIO can be safely and effectively adopted in clinical practice for these patients. This suggests a promising alternative in medical settings, where identifying lymph nodes accurately is crucial for treatment planning.
Our findings highlight that SPIO successfully identified sentinel lymph nodes in about 98.1% of cases, while the standard method achieved a detection rate of 94.6%. When examining the number of lymph nodes retrieved, SPIO demonstrated superior performance, with an average of 2.26 nodes detected compared to 1.86 with the conventional approach.
The overall quality of the studies reviewed was considered good, indicating that we can reliably say SPIO can be safely and effectively adopted in clinical practice for these patients. This suggests a promising alternative in medical settings, where identifying lymph nodes accurately is crucial for treatment planning.
Read More
User Reviews
USERS' SCORE
Good
Based on 5 Reviews
8.6
9.5
Significant improvement
These pills are excellent. My father is a cancer patient and was incredibly weak with a hemoglobin level of just 50 in August. After two months of taking these pills, his hemoglobin rose to 106. I’m really pleased with the results.
9.5
Iron level recovery
I ordered this for a cancer patient whose iron was depleted due to chemotherapy. We tried other kosher iron supplements without success until we switched to Solgar gentle iron. Her levels began to rise, and she no longer needs transfusions after taking it first thing in the morning with vitamin C.
Read More
8.8
Improved blood test
My mother underwent complete esophageal removal due to cancer, which led to severe anaemia. Despite trying various iron supplements and treatments over three years, her condition did not improve. However, after consistently drinking this supplement, her blood test results improved during regular health checks a few months later. I also advised others to consume it after meals to alleviate stomach discomfort, which seems to be effective. I’ve noticed a reduction in dizziness too. However, it’s currently out of stock, and I hope it is restocked soon.
Read More
8.8
No side effects
My mum has cancer and consistently suffers from low haemoglobin. We regularly use SOLGAR supplements, which compare favourably to traditional pharmacy drugs. They do not cause side effects like constipation and have helped maintain normal haemoglobin levels. I highly recommend this product.
Read More
3.8
Ineffective for cancer
My mother-in-law suffered from cancer with critically low levels of haemoglobin and iron. Despite taking these vitamins and adhering to all guidelines—like avoiding zinc and calcium—there was no increase in her iron or haemoglobin levels. While there were no reported side effects, I believe this supplement may not be effective for those with serious issues.
Read More
